Skip to content

Pamela L. Zeitlin, MD, MPhil, PhD

Make an Appointment
Pamela L. Zeitlin

Pamela L. Zeitlin, MD, is a board certified pediatric pulmonologist. Dr. Zeitlin specializes in asthma, bronchiectasis, cystic fibrosis, and many other pediatric respiratory conditions. She serves as Chair of the Department of Pediatrics.

Special Interests

My main area of expertise is in translational research in cystic fibrosis with a focus on chloride channels, protein chaperones, F508del pathophysiology and protein rescue in CF. I also have a role in pediatric asthma research. I have conducted investigator- initiated trials of 4-phenylbutyrate as a corrector in CF, anti-inflammatories in CF, Adeno-associated Viral gene therapy in CF, and many others. I held the IND for 4-phenylbutyrate for CF and hold the INDs for digitoxin and glycerolphenylbutyrate in CF. I also am a basic science investigator working in the area of chloride channels, proteomics, and protein trafficking. My laboratory is a translational environment where graduate students, clinical fellows, postdoctoral fellows and faculty can work collaboratively to advance our fundamental knowledge about CF airways disease.     



1976 - 1980
Yale, MPhil in Cell Biology
1976 - 1983
Yale, MD
1976 - 1983
Yale, PhD
1972 - 1976
Stanford University, BS in Biology


1983 - 1984
The Johns Hopkins Hospital, Pediatrics


1984 - 1986
The Johns Hopkins Hospital, Pediatrics


1986 - 1988
The Johns Hopkins Hospital, Pediatric Pulmonology

Awards & Recognition

2015-2016: Best Doctor's in America - Best Doctor's Inc.
2012: Elizabeth Rich Award, American Thoracic Society
2007: George Will Comstock Award, Maryland Thoracic Society
2006: Maryland Innovator of the Year
1988: Young Investigators' Certificate of Merit, The Johns Hopkins University School of Medicine
1983: Outstanding M.D./Ph.D. Student Award, Yale University
1972: Presidential Scholar for State of Hawaii

Board Certification

2006: Recertification, Diplomate Pediatric Pulmonary, 2007-2017
1992: Diplomate of Pediatric Pulmonology, American Board of Pediatrics, recertified 1998 until 2006
1988: American Board of Pediatrics, Permanent Certificate

Professional Memberships

National Societies:
American Association for the Advancement of Science
American Thoracic Society (Associate) Chair, Pediatric Assembly (5/2007-5/2009)
American College of Chest Physicians (Fellow)
American Physiological Society

Local Societies:
Maryland Lung Association

National Scientific Committees:
Question Writing Committee, General Pediatrics, American Board of Pediatrics (2013-present)
Member, Lung Cellular and Molecular Immunology study section (2008-2012)
Gilead Sciences Research Scholars Program review committee (2011)
Member, CRRC, NCRR, GCRC study section (2003-2007)
Chair-Elect, Subboard of Pediatric Pulmonology, American Board of Pediatrics
Chair, Pediatric Program Subcommittee of the American Thoracic Society
Subboard of Pediatric Pulmonology, American Board of Pediatrics (1999 - 2005)
National Institutes of Health Medical Biochemistry Study Section (1996- 2000)
National Institutes of Health, Special Emphasis Panels, Program Project Reviews (1994-96)

International Scientific Committees:
American Thoracic Society Pediatric Planning Committee (2010-present)
American Thoracic Society Pediatric Program Committee Chair Elect (2007)
American Thoracic Society Program Review Committee (2004-05)
Canadian Cystic Fibrosis Foundation Scientific Review Committee (2000-2003)
American Thoracic Society Program Planning Committee (2002)

Local Scientific Committees:
Maryland Lung Association, Executive Committee (1998-2000)
Maryland Lung Association, awards and grant committee (1991-95)


Henry KR, Lee S, Walker D, Zeitlin PL. Direct interactions between ENaC gamma subunit and ClCN2 in cystic fibrosis epithelial cells. Physiol Rep. 2015 Jan 27;3(1). pii: e12264. doi: 10.14814/phy2.12264. Print 2015 Jan 1.

Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators (Zeitlin PL). Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatr Pulmonol. 2013 Oct;48(10):943-53.

Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; for the Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014 May 15. pii: S2213-2600(14)70100-6. In press.

Lee S, Henderson MJ, Schiffhauer E, Despanie J, Henry K, Kang PW, Walker D, McClure ML, Wilson L, Sorscher EJ, Zeitlin PL. Interference with ubiquitination in CFTR modifies stability of core glycosylated and cell surface pools. Mol Cell Biol. 2014 Apr 28. [Epub ahead of print] PMCID: PMC4097669.

Schiffhauer, E, Vij N, Kovbasnjuk, O, Kang PW, Walker D, Lee S, Zeitlin, PL. Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelial. Am J Physiol Lung Cell Mol Physiol 2013 Mar 1;304(5):L324-31.

Teaching & Professional Positions

2001-2016: Professor of Pediatrics, Johns Hopkins University School of Medicine
1994-2001: Associate Professor of Pediatrics, Johns Hopkins University School of Medicine
1989-1994: Assistant Professor of Pediatrics, Johns Hopkins University School of Medicine
1988-1989: Instructor in Pediatrics, Johns Hopkins University School of Medicine

Conflicts of Interest

National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.